Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study for Patients with Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Signs a Clinical Research Agreement with Amal for the Evaluation of Combination Therapy to Treat Stage IV Colorectal Cancer
Shots:
- The INMARK study involves assessing of Ofev (nintedanib) vs PBO in 347 patients with IPF for 12 wks., followed by an open label period of 40 wks.
- The study resulted @12 wks lower rate of FVC decline (18.5 vs 13.1), with no rate of change in CRPM, 29% of the subjects experienced FVC decline of ≥10%
- Ofev is a tyrosine kinase inhibitor, shown to slow disease progression by reducing lung function decline and was also included in updated international treatment guidelines for IPF in 2017, approved in 70+ countries including the US, EU and Japan for IPF
Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Australia247